Module 7 Assignment

585.751.81 Immunoengineering

1. Here are some examples of recent start-ups tackling challenges related to infectious diseases, and pick one and research further: (15 points)

* Karius
* Moderna
* Day Zero Diagnostics
* VIR Biotechnology
* IDbyDNA
* Vaxess
* You may also choose a start-up not found on this list that you find interesting

**VIR Biotechnology**

As you research, answer briefly (1-2 sentences for each):

1. What does their technology do and what disease is targeted?

VIR Biotechnology has built a monoclonal antibody (mAB) discovery platform and a T Cell-Based Viral platform enabling to target a range of infectious diseases such as Chronic Hepatitis Delta (CHD), Hepatitis B (CHB), HIV, respiratory syncytial virus (RSV), Influenza, COVID 19 and pre-cancerous human papillomavirus (HPV) lesions.

1. What problem does their technology solve?

VIR Technology leverages the human immune system to fight viruses, employing machine learning and artificial intelligence, to engineer effective medicine from human-derived antibodies.

1. What stage of development are they at?

The FDA has granted approval for the COVID 19 medicine, while the remainder of the drug pipeline is either in preclinical or Phase 2 clinical trials.

1. A new diagnostic test is being developed for tuberculosis. Tests with characterized patient samples have been performed on the new test. Values below correspond to the number of samples in the test positive for tuberculosis. (10 points)

* Calculate the sensitivity and specificity of the test for each group and also for all groups combined.
* Also, comment on the utility of this test based on these criteria.

HIV– groups (n = 222)

TB+ = 50/54

Latent TB = 8/62

Nontuberculosis mycobacteria = 6/64

Healthy controls = 0/42

|  |  |  |
| --- | --- | --- |
|  | **TB+, Latent TB** | **NonTb + Healthy** |
| **Positive Test Result** | 58 | 6 |
| **Negative Test Result** | 58 | 100 |
|  | 116 | 106 |
|  |  |  |
| **Sensitivity** | 0.5 |  |
| **Specificity** | 0.943396226 |  |

For people without HIV, the test has a 50% probability of correctly detecting TB in those who have it, this means that for people without HIV who have TB, the test performs no better than random chance. However, within the same group, the test shows a very high probability, ~ 94% of correctly identifying individuals without TB as healthy. For individuals without HIV who do not have TB, the test is very accurate classifying them as TB-free.

HIV+ groups (n = 180)

Pulmonary TB+ = 70/80

Extrapulmonary TB+ = 36/42

TB- = 6/58

|  |  |  |
| --- | --- | --- |
|  | **TB+, Extra.TB+** | **TB-** |
| **Positive Test Result** | 106 | 52 |
| **Negative Test Result** | 16 | 6 |
|  | 122 | 58 |
|  |  |  |
| **Sensitivity** | 0.868852459 |  |
| **Specificity** | 0.103448276 |  |

In the group of people with HIV, the test performs differently; It can significantly detect people with TB, achieving an accuracy of approximately 86%, which means that for people with HIV who have TB, the test effectively detects the infection in most cases. However, the test performs poorly for healthy individuals within the same group. It struggles to accurately classify healthy people as disease-free.

**HIV- + HIV+**

|  |  |  |
| --- | --- | --- |
|  | **TB+** | **TB-** |
| **Positive Test Result** | 164 | 58 |
| **Negative Test Result** | 74 | 106 |
|  | 238 | 164 |
|  |  |  |
| **Sensitivity** | 0.68907563 |  |
| **Specificity** | 0.646341463 |  |

Assuming that the experiment is representative of the number of people with HIV and without, including both healthy individuals and those with TB, the test’s overall ability to distinguish between TB+ and TB- individuals is subpar. Specifically, the test ability in detecting TB+ individuals and correctly identifying TB- people are approx. 68% and 64%. These performances could put on pause the approval for the test’s deployment.

1. Compare and contrast *Large scale screening* to *Mechanistic* *insight* approaches to discover new therapeutic targets. Please focus on the advantages and disadvantages of each approach. (15 points)

|  |  |  |
| --- | --- | --- |
|  | **Advantages** | **Disadvantages** |
| **Large scale screening** | * High throughput: due to automation allows the rapid screening of very large libraries of compounds against a specific target and can accelerate the identification of potential active compounds or hits. * Does not require prior knowledge for finding a novel drug. | * Initial set up costs of HTS technology could be significant. * May not be as specific as other technics (false positives/negatives). * May require the libraries to be established which could be time consuming and costly. * With an increase of throughput: loss of the physiological relevance, and impact on host toxicity. * Provides limited insights into the mechanistic action of the compounds. |
| **Mechanistic insight** | * Provides detailed insights into the molecular mechanisms and pathways through which compounds exert their effects. * Insights of mechanism of actions can help in predicting and understanding drug resistance, adverse effects and could reduce the failures rates in later stages of drug development. * Allows rational design and can lead to a more targeted and potentially more effective therapy. * Enable to answer theoretical and fundamental questions with simulation. | * Low throughput: compared to HTS, analyzes of fewer compounds or hypotheses at a time. * Requires understanding of the disease. * Requires more resources, time and potentially more sophisticated tools and models from researchers. * Compared to other methods has a higher chance of failure. |

1. Compare and contrast the four major different types of biologic therapeutic approaches. In your analysis answer: (20 points)

* When would you want to use each approach for infectious disease?
* What is one of the major advantages and disadvantages to each approach?
* What design criteria are shared between approaches in creating a therapy?

1. Design a biomaterial therapeutic to treat one of the following infectious diseases:

* Tuberculosis (Bacteria)
* Malaria (Parasite)
* HIV (Virus)

In your consideration of your design, please list specifically how the therapeutic was designed with design constraints such as:

1. Manufacturing/Cost
2. Safety
3. Specificity
4. Potency
5. Biomaterial properties – e.g. stiffness, degradability, size, shape, etc.

**Malaria Biomaterial Therapeutic**

Malaria is a parasitic infection transmitted to humans by the Plasmodium species, with 5 species known to infect humans. Among them, *P.falciparum* and *P.vivax* are the most prevalent. The disease’s lifecycle begins when Anopheles mosquitoes, having fed on the blood containing parasitized RBCs (pRBCs) of an infected individual, transmit the parasite to a new human host [1].

Historically, quinine (QN) has been the most effective in malaria treatment, though lacks efficacity against *P.falciparum* and has triggered resistance. In response, artemisin-based combination therapy (ACT) has shown the most promising results in treating malaria.

These therapies combine artemisinin-derivatives with chloroquine (CQ) and include artesunate (ATS) with amodiaquine, mefloquine, and proguanil [1].

We use PLGA as the base material for our nanoparticle delivery system. PLGA nanoparticles have been extensively studied for drug delivery, known for their safety and biocompatibility in clinical settings. They degrade into non-toxic byproducts that the body can easily eliminate. Producing these nanoparticles is cost-effective due to streamlined production processes.

To enhance treatment success, we might also use big data to identify biomarkers to classify individuals in group who could benefit most from a specific ACT treatment. We then encapsulate an ACT therapeutic within the PLGA nanoparticles.

One target for increasing drug delivery specificity is the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1), found on the surface of pRBCs. We attach antibodies against PfEMP1 to the nanoparticles [1].

Given the acidic environment (pH 5.0-5.4) inside the Plasmodium’s digestive vacuole, we incorporate a pH sensitive linker that releases the drug right at the infection site, boosting the treatment’s effectiveness [1].

Research by by Najer et al. [2], polymer-based RBC membrane mimicking RBC membrane, can not only block the parasite from entering new cells but showed high binding affinity with P.falciparum merozoite surface protein1. We design the nanoparticles with specific stiffness that mimics RBCs, to help them stay in circulation longer.

Developing this treatment will involve extensive lab and animal studies to refine its safety, efficacy, and precision. Preclinical trials will assess its performance against different strains of malaria and evaluate any potential side effects.

[1] L. N. Borgheti-Cardoso *et al.*, “Promising nanomaterials in the fight against malaria,” *J. Mater. Chem. B*, vol. 8, no. 41, pp. 9428–9448, 2020, doi: 10.1039/d0tb01398f

[2] A. Najer *et al.*, “Nanomimics of Host Cell Membranes Block Invasion and Expose Invasive Malaria Parasites,” *ACS Nano*, vol. 8, no. 12, pp. 12560–12571, 2014, doi: 10.1021/nn5054206